Synthesis and characterization of a iodine-125-labeled pyrrolo[1,2-a]thieno[3,2-e]pyrazine and evaluation as a potential 5-HT4R SPECT tracer
摘要:
In the aim to find new radiotracers for the in vivo imaging of 5-HT4 receptors by ultra-high resolution quantitative SPECT, we have developed the synthesis of a radioiodinated 5-HT4 ligand using an iododestannylation procedure. The [I-125]-ligand was obtained in a high radiochemical yield. Preliminary autoradiographic and ex vivo studies failed to show a specific labeling of 5-HT4 receptors. (C) 2010 Published by Elsevier Masson SAS.
[EN] EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS<br/>[FR] POTENTIEL THÉRAPEUTIQUE ÉTENDU DANS DES ANTIMICROBIENS À NITROHÉTÉROARYLE
申请人:UNIV CALIFORNIA
公开号:WO2014205414A1
公开(公告)日:2014-12-24
Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to imidazole, thiazole, and furan derivatives and their use as therapeutic agents.
Click and Pick: Identification of Sialoside Analogues for Siglec-Based Cell Targeting
作者:Cory D. Rillahan、Erik Schwartz、Ryan McBride、Valery V. Fokin、James C. Paulson
DOI:10.1002/anie.201205831
日期:2012.10.29
Click ‘n’ chips: Azide and alkyne‐bearing sialic acids (purple diamond; see picture) were subjected to high‐throughput click chemistry to generate a library of sialic acid analogues. Microarray printing of the library and screening with the siglec family of sialic‐acid‐binding proteins, led to the identification of high‐affinity ligands for siglec‐9 and siglec‐10.
2-polycyclic propynyl adenosine analogs having A2A agonist activity
申请人:Rieger M. Jayson
公开号:US20060040889A1
公开(公告)日:2006-02-23
The invention provides compounds having the following general formula (I):
wherein X, R
1
, R
2
, R
7
and Z are as described herein.
这项发明提供了具有以下一般式(I)的化合物:
其中X、R1、R2、R7和Z如本文所述。
[EN] NOVEL INDOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS<br/>[FR] NOUVEAUX DÉRIVÉS D'INDOLE UTILES EN TANT QU'AGENTS ANTIDIABÉTIQUES
申请人:MERCK SHARP & DOHME
公开号:WO2014139388A1
公开(公告)日:2014-09-18
Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
The enzyme nicotinamidephosphoribosyltransferase is both a key intracellular enzyme for NAD biosynthesis (iNAMPT) and an extracellular cytokine (eNAMPT). The relationship between this latter role and the catalytic activity of the enzyme is at present unknown. With the intent of discovering inhibitors specifically able to target eNAMPT, we increased the polarity of MV78 (EC50 = 5.8 nM; IC50 = 3.1 nM)